摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-乙基-3-氮杂环丁醇盐酸盐 | 935668-00-1

中文名称
3-乙基-3-氮杂环丁醇盐酸盐
中文别名
——
英文名称
3-ethyl-3-azetidinol hydrochloride
英文别名
3-Ethylazetidin-3-ol hydrochloride;3-ethylazetidin-3-ol;hydrochloride
3-乙基-3-氮杂环丁醇盐酸盐化学式
CAS
935668-00-1
化学式
C5H11NO*ClH
mdl
——
分子量
137.609
InChiKey
PIMOMOKLCCGODE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.15
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    32.3
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

反应信息

  • 作为反应物:
    描述:
    3-乙基-3-氮杂环丁醇盐酸盐 、 AN10248 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.5h, 以37%的产率得到(3-ethyl-3-hydroxyazetidin-1-yl)(5-(1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yloxy)pyrazin-2-yl)methanone
    参考文献:
    名称:
    苯并氧杂硼杂环戊烷抗疟剂。第5部分。新型酰胺吡唑基氧基苯并恶唑的前导物优化和临床前候选物的鉴定
    摘要:
    为了确定具有令人满意的抗疟活性,理化性质,药代动力学特征,体内功效和安全性特征的分子,对羧酰胺基吡嗪酰氧基苯并氧杂硼酸酯进行了研究。这项优化工作发现了46个,满足了我们的目标候选人档案。化合物46对培养的恶性疟原虫具有优异的活性,并且在感染的小鼠体内对恶性疟原虫和伯氏疟原虫具有体内活性。它在小鼠,大鼠和狗中表现出良好的PK特性。它对其他11种恶性疟原虫非常活跃菌株,大多数对氯喹和乙胺嘧啶有抗性。46种体外快速寄生虫减少和体内寄生虫清除率特征与青蒿素和氯喹(两种速效抗疟药)相似。当口服剂量高达2000 mg / kg时,在Ames分析,体外微核分析和体内大鼠微核分析中均无遗传毒性。这种新颖的苯并氧杂硼酸酯的综合性能支持其向临床前发展的进程。
    DOI:
    10.1021/acs.jmedchem.7b00621
  • 作为产物:
    描述:
    1-(二苯基甲基)-3-乙基-3-氮杂环丁醇盐酸 、 palladium 10% on activated carbon 、 氢气 作用下, 以 甲醇 为溶剂, 生成 3-乙基-3-氮杂环丁醇盐酸盐
    参考文献:
    名称:
    苯并氧杂硼杂环戊烷抗疟剂。第5部分。新型酰胺吡唑基氧基苯并恶唑的前导物优化和临床前候选物的鉴定
    摘要:
    为了确定具有令人满意的抗疟活性,理化性质,药代动力学特征,体内功效和安全性特征的分子,对羧酰胺基吡嗪酰氧基苯并氧杂硼酸酯进行了研究。这项优化工作发现了46个,满足了我们的目标候选人档案。化合物46对培养的恶性疟原虫具有优异的活性,并且在感染的小鼠体内对恶性疟原虫和伯氏疟原虫具有体内活性。它在小鼠,大鼠和狗中表现出良好的PK特性。它对其他11种恶性疟原虫非常活跃菌株,大多数对氯喹和乙胺嘧啶有抗性。46种体外快速寄生虫减少和体内寄生虫清除率特征与青蒿素和氯喹(两种速效抗疟药)相似。当口服剂量高达2000 mg / kg时,在Ames分析,体外微核分析和体内大鼠微核分析中均无遗传毒性。这种新颖的苯并氧杂硼酸酯的综合性能支持其向临床前发展的进程。
    DOI:
    10.1021/acs.jmedchem.7b00621
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS
    申请人:Bayer AG
    公开号:EP3800188A1
    公开(公告)日:2021-04-07
    The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.
    本申请涉及用于治疗和/或预防疾病的新的吡唑嘧啶生物,以及将它们用于生产用于治疗和/或预防人类和动物疾病的药物,尤其是增殖性疾病、自身免疫性疾病、代谢和炎症性疾病,这些疾病的特点是免疫系统过度反应,特别是风湿性疾病、炎症性皮肤病、心血管疾病、肺部疾病、眼病、神经系统疾病、疼痛疾病和癌症,在人类中,以及动物的过敏性/或炎症性疾病,特别是异位性皮炎和/或跳蚤过敏性皮炎,尤其是在家养动物中,特别是在狗中。
  • [EN] PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PEPTIDE DÉFORMYLASE
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2009061879A1
    公开(公告)日:2009-05-14
    The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.
    本发明涉及某些2-(烷基)-3-[2-(5--4-嘧啶基)基]-3-氧代丙基}羟甲酰胺衍生物,含有它们的组合物,以及这些化合物在抑制细菌肽变形酶(PDF)活性和治疗细菌感染中的用途。具体而言,该发明涉及式(I)的化合物,其中R1、R2和R3在此有定义,并且其药用盐。本发明的这些化合物是细菌肽变形酶抑制剂,可用于治疗细菌感染。
  • TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE
    申请人:Daiichi Sankyo Company, Limited
    公开号:EP1942109A1
    公开(公告)日:2008-07-09
    A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or an alkoxy group, R3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R4 represents hydrogen atom, or an alkyl group, Z1 and Z2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z3 represents cyano group, an alkyl group, an alkenyl group and the like, Z4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and ---- represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.
    一个由通式(1)表示的化合物,其中[X1和X2代表氢原子,卤素原子,羟基等,R1代表苯基,R2代表烷基,烯基或烷氧基,R3代表氢原子,卤素原子,羟基或烷氧基,R4代表氢原子或烷基,Z1和Z2代表氢原子,卤素原子,羟基等,Z3代表基,烷基,烯基等,Z4代表烷基,烯基,炔基等,----代表单键或双键],对包括药物耐药细胞在内的癌细胞表现出高抗肿瘤效果。
  • PEPTIDE DEFORMYLASE INHIBITORS
    申请人:Qin Donghui
    公开号:US20090306066A1
    公开(公告)日:2009-12-10
    The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.
    本发明涉及某些2-(烷基)-3-[2-(5--4-嘧啶基)基]-3-氧代丙基}羟基甲酰胺衍生物,包含它们的组合物,这些化合物在抑制细菌肽变形酶(PDF)活性和治疗细菌感染方面的使用。具体而言,本发明涉及式(I)的化合物:其中R1,R2和R3在此定义,并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂,可用于治疗细菌感染。
  • Taxane Compound Having Azetidine Ring Structure
    申请人:Uoto Kouichi
    公开号:US20090186868A1
    公开(公告)日:2009-07-23
    A compound represented by the general formula (1) [X 1 and X 2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R 1 represents a phenyl group, R 2 represents an alkyl group, an alkenyl group, or an alkoxy group, R 3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R 4 represents hydrogen atom, or an alkyl group, Z 1 and Z 2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z 3 represents cyano group, an alkyl group, an alkenyl group and the like, Z 4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.
    一种化合物由通式(1)表示 [其中X1和X2代表氢原子、卤素原子、羟基等,R1代表苯基,R2代表烷基、烯基或烷氧基,R3代表氢原子、卤素原子、羟基或烷氧基,R4代表氢原子或烷基,Z1和Z2代表氢原子、卤素原子、羟基等,Z3代表基、烷基、烯基等,Z4代表烷基、烯基、炔基等,且表示单键或双键],对包括耐药细胞在内的癌细胞具有高抗肿瘤效果。
查看更多